Duchenne News Tags: Wave Life Sciences

November 24, 2025

Wave Life Sciences Shares Community Letter Detailing Initiation of Part C of FORWARD-53 Clinical Trial

On November 24, 2025, Wave Life Sciences announced they have initiated Part C of FORWARD-53, a clinical trial evaluating the investigational molecule WVE-N531 in boys with Duchenne muscular dystrophy (DMD)...

Read More

March 26, 2025

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

On March 26, 2025, Wave Life Sciences Ltd. announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with...

Read More

September 30, 2024

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Press release and Community Letter updates from Wave Life Sciences.

Read More

December 19, 2023

Wave Life Sciences announces the initiation of dosing in Phase 2 FORWARD-53 study for boys with Duchenne muscular dystrophy amenable to exon 53 skipping

Wave Life Sciences Community Letter with information on Phase 2 FORWARD-53 study for Duchenne.

Read More

April 5, 2023

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Wave Life Sciences announces financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Read More

December 20, 2022

Wave Life Sciences Announces Positive Update from Phase 1b/2a Study of WVE-N531 in Duchenne

Wave Life Sciences announces positive update from Phase 1b/2a study of WVE-N531 in Duchenne

Read More